ORIC Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies intended to overcome cancer treatment resistance. The company has no approved products and has not generated revenue from product sales. The report covers the quarter ended March 31, 2024, filed May 6, 2024.
Clinical-stage programs include ORIC-114, targeting EGFR and HER2 exon 20 alterations; ORIC-944, targeting PRC2/EED in prostate cancer; and ORIC-533, targeting CD73 in multiple myeloma. The company also maintains discovery-stage programs.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $22.0 million | $19.5 million | +$2.4 million |
| General and administrative expense | $7.0 million | $6.2 million | +$0.9 million |
| Total operating expenses | $29.0 million | $25.7 million | +$3.3 million |
| Other income, net | $4.0 million | $1.7 million | +$2.2 million |
| Net loss | $25.0 million | $23.9 million | Loss increased $1.1 million |
| Basic and diluted loss per share | $0.37 | $0.53 | Per-share loss decreased |
| Net cash used in operating activities | $30.2 million | $20.6 million | Use increased $9.6 million |
| Cash, cash equivalents and investments | $331.5 million | Not clearly provided as a comparable total | Not directly comparable from the filing text |
At March 31, 2024, cash and cash equivalents were $56.4 million, short-term investments were $260.4 million, and long-term investments were $14.7 million. Total assets were $350.8 million, total liabilities were $22.1 million, and stockholders’ equity was $328.6 million. The filing reports no debt financing or material debt balance.
Research and development spending increased primarily because of greater investment in ORIC-114 and ORIC-944 and higher personnel costs, partly offset by lower ORIC-533 and discontinued or unallocated costs. Stock-based compensation was $5.0 million, compared with $3.6 million in the prior-year quarter.
Material changes versus the prior comparable period
- Operating expenses increased 12.9% to $29.0 million, driven by higher research and development and general and administrative costs.
- Other income increased to $4.0 million, primarily reflecting higher interest income from larger cash and investment balances.
- Net loss increased by $1.1 million despite the increase in other income.
- Basic and diluted weighted-average shares outstanding increased to 67.3 million from 45.1 million, primarily reflecting equity financing activity; the lower loss per share therefore does not indicate improved profitability.
- Operating cash usage increased to $30.2 million from $20.6 million. Investing activities used $61.9 million in Q1 2024, primarily for purchases of investments, compared with $12.8 million of investing cash inflow in Q1 2023.
- Financing activities provided $125.0 million from the January 2024 private placement of 12.5 million common shares at $10.00 per share. Net proceeds were approximately $124.8 million after expenses.
- The company filed a Form S-3ASR and prospectus supplement permitting sales of up to $200 million of common stock under its ATM program.
Guidance, outlook, commentary and risks
Management expects existing cash, cash equivalents and investments to fund the current operating plan into late 2026, and believes working capital is sufficient for at least the next twelve months. This is a forward-looking estimate subject to clinical, regulatory, manufacturing, enrollment, cost and financing uncertainties.
- ORIC-114: two provisional recommended Phase 2 dose levels, 80 mg and 120 mg once daily, were selected in April 2024. Dose-expansion cohorts and a first-line EGFR exon 20 NSCLC extension cohort were initiated. Updated Phase 1b data are expected in the first half of 2025.
- ORIC-944: the company is proceeding with a combination study with androgen-receptor inhibitors in metastatic prostate cancer and expects to provide a program update in mid-2024.
- ORIC-533: the company is completing its Phase 1b trial and intends to evaluate strategic partnerships for combinations with immune-based antimyeloma therapies.
- Management expects research and development expenses and operating losses to increase substantially as programs advance into larger and later-stage trials. The company does not expect meaningful revenue unless and until a product candidate receives regulatory approval and is commercialized.
- The company will require substantial additional capital to complete development and commercialization. Additional equity, debt, collaboration or licensing financing may be unavailable or may dilute existing stockholders or restrict operations.
- Key risks include failure or delay in clinical trials, adverse safety findings, insufficient efficacy, patient-enrollment challenges, regulatory rejection, reliance on single-source manufacturers and CROs, intellectual-property disputes, competition, supply-chain disruption, cybersecurity incidents and changing healthcare reimbursement or pricing rules.
- The filing states that the Chief Business Officer was found liable by a jury on April 5, 2024, in an SEC insider-trading action concerning transactions unrelated to ORIC. Appeal rights remain available, and potential sanctions could affect his ability to serve as an officer.
- The filing identifies an inquiry regarding a potential breach of a confidentiality agreement related to the CD73 inhibitor program; it does not state that a formal claim or litigation has been filed.
- Management reported that disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2024, with no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Whether clinical data for ORIC-114 and ORIC-944 support continued advancement, dose selection and combination strategies, including the timing and content of future readouts.
- Whether the projected cash runway to late 2026 remains valid as clinical programs expand and operating cash use increases.
- The potential dilution and market impact from the January 2024 equity issuance, the outstanding pre-funded warrants, stock options, RSUs and the $200 million ATM facility.
- The status and potential consequences of the Chief Business Officer’s SEC-related litigation and the pending confidentiality inquiry concerning the CD73 program.
- Clinical-trial enrollment, safety, efficacy, manufacturing supply and regulatory requirements for all three lead programs.
- Future financing needs, collaboration terms and any licensing milestones, royalties or other contingent obligations, particularly under the Voronoi license.
- The company’s ability to generate any product revenue, since it has no approved products and has incurred an accumulated deficit of $459.9 million as of March 31, 2024.